Browsing by Author "Atalay F."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis
    (Yonsei University College of Medicine, 2003) Aki S.; Eskiyurt N.; Akarirmak Ü.; Tüzün F.; Eryavuz M.; Alper S.; Arpacioǧlu O.; Atalay F.; Kavuncu V.; Kokino S.; Kuru Ö.; Nas K.; Özerbil Ö.; Savaş G.; Sendur Ö.F.; Soy D.; Akyüz G.
    The aim of our study was to evaluate the upper gastrointestinal (GI) tract side effect profile in 759 female patients that had taken alendronate (10 mg/day), for at least 6 months, for the treatment of osteoporosis, in relation to the safety of alendronate and the compliance of patients to its absorption rules. This study was a multicentered retrospective, clinical, nonplacebo controlled, study of 759 female subjects carried out at 26 centres in 6 different regions of Turkey. The mean age of our patients was 62.6 ± 8.6, with 51.2%in the age range 60 to 69 years. 158 patients (20.8%) were considered to have upper GI tract complaints with nausea as the most often encountered symptom. Of the subjects with upper GI tract complaints, 20% reported discontinued drug use, and 30% reported the requirement of an additional drug in order to abolish their complaints. Approximately 537 (71%) of the patients stated they had been given written information about the administration of the drug, and at least 93 patients (12%) and 73 patients (18.4%) acknowledged non compliance with the safety and absorption rules, respectively. In our study, no significant difference was found between the adherence to the safety measures and upper GI tract complaints (p>0.05), but that upper GI tract complaints were higher in patients taking additional medication to alendronate (p<0.05).
  • No Thumbnail Available
    Item
    Prevalence of asthmatic smokers: Turkish experience (PASTE Study)
    (Blackwell Publishing Ltd, 2014) Yildiz F.; Dursun A.B.; Disçi R.; Abadoglu O.; Atalay F.; Ates G.; Buyukoglan H.; Ceyhan B.; Ceylan E.; Deveci F.; Ediger D.; Ekici A.; Erdinc M.; Gemicioglu B.; Goktalay T.; Meral M.; Mungan D.; Ogus C.; Ozge C.
    Background: Although both asthma and smoking are major health problems worldwide, smokers are often excluded from asthma studies. Objectives: It was aimed to verify the prevalence of asthmatic smokers in Turkey and assess the effects of smoking based on clinical parameters, exacerbations and hospitalizations because of lack of national data about the prevalence of smoking among asthmatics. Methods: The study protocol was comprised of a retrospective questionnaire. The asthmatic patients were followed in the outpatient clinics of 18 tertiary hospitals selected from seven different geographical regions in Turkey. We evaluated demographic data, smoking habits, asthma-related diseases, respiratory function and emergency visits. Results: The study population included 1385 patients (M/F: 343/1042), and the mean age was 45.1±14.0 years. Current and former smoking prevalence was 11.4% and 15.1%, respectively. Smoker rates were higher in males and younger asthmatics compared with females and older asthmatics (P<0.01 and P<0.05, respectively). Smoking history ranged from 0.20 to 90 pack-years (the mean was 12.9), and smokers had a higher level of education compared with nonsmokers (P<0.01). Socioeconomically, the most developed region had the highest rate of smoker asthmatics (33.9%; P=0.014). There was an increase in the number of exacerbations in smoker asthmatics during the previous year, but it was not statistically significant (P>0.05). Conclusion: We showed that the smoking prevalence in Turkey was lower in asthmatics (11.4%) compared with the general population (44.5%). Nevertheless, every effort should be made to encourage asthmatics to stop smoking because smoking is a modifiable risk factor for adverse asthma health outcomes. © 2013 John Wiley and Sons Ltd.